Q-omics provides the consensus-scored FRG1-DT profile across patient tissues and cancer cell-line models. FRG1-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FRG1-DT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FRG1-DT RNA expression shows 19,196 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FRG1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG1-DT survival associations across molecular data types. FRG1-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG1-DT RNA expression–survival associations across cancer types. High FRG1-DT expression shows unfavorable associations in ACC and LIHC, but favorable associations in UCS, BRCA, PAAD and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FRG1-DT RNA expression.
This table summarizes FRG1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG1-DT shows lower tumor expression in KIRC, THCA, KICH and BRCA and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher FRG1-DT RNA expression in normal versus tumor tissue (log2 FC = −0.443, t-test p < 0.001).
This table shows molecular features associated with FRG1-DT in patient tissues and cancer cell lines. In patient samples, FRG1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
